Wave Life Sciences Ltd. (NASDAQ:WVE) Position Boosted by Emerald Advisers LLC

Emerald Advisers LLC boosted its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 9.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,162,369 shares of the company’s stock after acquiring an additional 280,859 shares during the period. Wave Life Sciences comprises about 1.5% of Emerald Advisers LLC’s investment portfolio, making the stock its 12th biggest holding. Emerald Advisers LLC owned about 2.07% of Wave Life Sciences worth $39,119,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of WVE. Maverick Capital Ltd. boosted its stake in Wave Life Sciences by 31.0% in the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after purchasing an additional 2,378,159 shares during the period. Vanguard Group Inc. lifted its stake in shares of Wave Life Sciences by 10.2% in the 4th quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company’s stock valued at $39,368,000 after purchasing an additional 294,956 shares during the last quarter. State Street Corp raised its holdings in Wave Life Sciences by 2.6% in the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company’s stock worth $19,034,000 after acquiring an additional 57,822 shares during the period. Geode Capital Management LLC raised its holdings in Wave Life Sciences by 14.3% in the 3rd quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company’s stock worth $18,615,000 after acquiring an additional 283,419 shares during the period. Finally, FMR LLC raised its holdings in Wave Life Sciences by 174.5% in the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after acquiring an additional 979,110 shares during the period. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Trading Down 0.8 %

Wave Life Sciences stock opened at $9.59 on Friday. The company has a fifty day simple moving average of $10.92 and a 200 day simple moving average of $11.55. Wave Life Sciences Ltd. has a 1-year low of $4.25 and a 1-year high of $16.74. The company has a market cap of $1.47 billion, a P/E ratio of -8.64 and a beta of -1.04.

Wave Life Sciences (NASDAQ:WVE) last announced its earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. On average, equities research analysts forecast that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Insider Activity

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at $3,238,019.07. The trade was a 33.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on WVE. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 5th. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.